Industry
Biotechnology
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.
Loading...
Open
4.33
Mkt cap
38M
Volume
391K
High
4.34
P/E Ratio
-1.01
52-wk high
4.58
Low
4.33
Div yield
N/A
52-wk low
1.37
Portfolio Pulse from Benzinga Insights
October 24, 2024 | 7:00 pm
Portfolio Pulse from Benzinga Newsdesk
October 24, 2024 | 6:53 pm
Portfolio Pulse from Benzinga Newsdesk
October 23, 2024 | 9:09 pm
Portfolio Pulse from Benzinga Newsdesk
October 23, 2024 | 1:20 pm
Portfolio Pulse from Benzinga Newsdesk
October 23, 2024 | 12:25 pm
Portfolio Pulse from Benzinga Newsdesk
October 23, 2024 | 12:03 pm
Portfolio Pulse from Benzinga Newsdesk
October 23, 2024 | 11:56 am
Portfolio Pulse from Benzinga Newsdesk
October 23, 2024 | 11:55 am
Portfolio Pulse from Benzinga Newsdesk
September 27, 2024 | 3:00 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.